BR0209020A - Composição farmacêutica de polialilamina - Google Patents

Composição farmacêutica de polialilamina

Info

Publication number
BR0209020A
BR0209020A BR0209020-1A BR0209020A BR0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A BR 0209020 A BR0209020 A BR 0209020A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polyallylamine
polymer
diluent
disclosed
Prior art date
Application number
BR0209020-1A
Other languages
English (en)
Inventor
John S Petersen
Steven Keith Burke
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR0209020A publication Critical patent/BR0209020A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA DE POLIALILAMINA". é descrita uma composição farmacêutica compreendendo um polímero de hidrocloreto de polialilamina estável na qual entre aproximadamente 4% a aproximadamente 12% por peso do polímero é um ânion cloreto e um transportador farmaceuticamente aceitável ou um diluente.
BR0209020-1A 2001-04-18 2002-04-10 Composição farmacêutica de polialilamina BR0209020A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
PCT/US2002/011408 WO2002085378A1 (en) 2001-04-18 2002-04-10 Low salt forms of polyallylamine

Publications (1)

Publication Number Publication Date
BR0209020A true BR0209020A (pt) 2004-08-10

Family

ID=23090248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209020-1A BR0209020A (pt) 2001-04-18 2002-04-10 Composição farmacêutica de polialilamina

Country Status (15)

Country Link
US (2) US7541024B2 (pt)
EP (1) EP1379258B1 (pt)
JP (2) JP5170932B2 (pt)
KR (1) KR20040018357A (pt)
CN (1) CN1290515C (pt)
AT (1) ATE331525T1 (pt)
AU (1) AU2002252632B2 (pt)
BR (1) BR0209020A (pt)
CA (1) CA2444587C (pt)
DE (1) DE60212819T2 (pt)
ES (1) ES2268013T3 (pt)
MX (1) MXPA03009572A (pt)
NZ (1) NZ528829A (pt)
WO (1) WO2002085378A1 (pt)
ZA (2) ZA200308065B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
WO2005032563A1 (en) * 2003-09-02 2005-04-14 Genzyme Corporation Method for reducing vascular inflammation
KR101223335B1 (ko) 2004-03-30 2013-01-17 리립사, 인크. 이온 결합 조성물
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP1951266A2 (en) 2005-09-02 2008-08-06 Genzyme Corporation Method for removing phosphate and polymer used therefore
CN101272762B (zh) 2005-09-15 2013-02-06 基酶有限公司 胺聚合物的小袋制剂
JP2009542653A (ja) * 2006-07-05 2009-12-03 ジェンザイム コーポレーション リン酸塩過剰血症のための鉄（ｉｉ）含有治療剤
JP2010504975A (ja) 2006-09-29 2010-02-18 ゲンズイメ コーポレーション アミドデンドリマー組成物
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
EP2016947A1 (en) 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009125433A2 (en) * 2008-04-08 2009-10-15 Usv Limited Process for preparation of amine polymer salt
US8404784B2 (en) * 2008-12-03 2013-03-26 Navinta Llc Manufacturing process of making polymeric amine salts
CA2765370A1 (en) * 2009-06-16 2010-12-23 Watson Pharma Private Limited Processes for the preparation of sevelamer carbonate
US9181364B2 (en) * 2010-02-24 2015-11-10 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
DK3287133T3 (da) 2013-06-05 2019-07-01 Tricida Inc Proton-bindende polymerer til oral indgivelse
KR102625115B1 (ko) * 2014-12-10 2024-01-12 트리시다, 인크. 경구 투여용 양성자-결합 폴리머
KR102655774B1 (ko) 2016-05-06 2024-04-05 트리시다, 인크. 산-염기 장애의 치료를 위한 조성물 및 방법
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
CA3079171C (en) 2017-10-16 2023-09-12 Fujifilm Corporation Therapeutic agent for hyperphosphatemia and particles
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
CN110753217B (zh) * 2019-10-28 2022-03-01 黑芝麻智能科技(上海)有限公司 色彩平衡方法和装置、车载设备以及存储介质
US11572355B2 (en) * 2020-07-16 2023-02-07 The Board Of Trustees Of The University Of Alabama Methods for synthesizing vinylidenes and alkenes
CN112047854B (zh) * 2020-10-20 2021-07-02 中国科学院长春应用化学研究所 一种n-乙烯基烷基酰胺的制备方法
WO2023023938A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
ES2980624T3 (es) * 2021-08-24 2024-10-02 Waterstone Pharmaceuticals Wuhan Co Ltd Polímeros, composiciones y métodos para tratar hiperuricemia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4222921A (en) * 1978-06-19 1980-09-16 Monsanto Company Polyamine/epihalohydrin reaction products
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
CA1220896A (en) 1983-11-10 1987-04-21 Susumu Harada Process for producing polymers of monoallylamine
US4614593A (en) * 1985-03-28 1986-09-30 Ethyl Corporation Demulsification of oil-in-water emulsions
IE914179A1 (en) * 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
WO1996021454A1 (en) * 1995-01-12 1996-07-18 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
JP2003183168A (ja) * 1997-04-04 2003-07-03 Chugai Pharmaceut Co Ltd リン酸結合性ポリマー含有製剤
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
AU2682499A (en) 1998-02-17 1999-08-30 Dimitri R. Kioussis Anion binding polymers and the use thereof
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6180754B1 (en) * 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core

Also Published As

Publication number Publication date
US8377428B2 (en) 2013-02-19
CN1290515C (zh) 2006-12-20
JP5170932B2 (ja) 2013-03-27
ZA200308065B (en) 2004-09-14
EP1379258A1 (en) 2004-01-14
JP2010111704A (ja) 2010-05-20
ES2268013T3 (es) 2007-03-16
CA2444587A1 (en) 2002-10-31
DE60212819D1 (de) 2006-08-10
CA2444587C (en) 2008-10-21
DE60212819T2 (de) 2006-11-23
JP5243466B2 (ja) 2013-07-24
JP2004526777A (ja) 2004-09-02
US20020159968A1 (en) 2002-10-31
US20100068167A1 (en) 2010-03-18
AU2002252632B2 (en) 2004-09-23
US7541024B2 (en) 2009-06-02
MXPA03009572A (es) 2004-02-12
WO2002085378A1 (en) 2002-10-31
HK1058620A1 (en) 2004-05-28
ATE331525T1 (de) 2006-07-15
CN1503676A (zh) 2004-06-09
ZA200308063B (en) 2005-01-17
NZ528829A (en) 2006-06-30
EP1379258B1 (en) 2006-06-28
KR20040018357A (ko) 2004-03-03

Similar Documents

Publication Publication Date Title
BR0209020A (pt) Composição farmacêutica de polialilamina
SE0300010D0 (sv) Novel Compounds
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
LU92853I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
HK1039108A1 (zh) 以n-氰甲基酰胺作为蛋白酶抑制剂
DE602004024375D1 (de) Carboxamidderivate
LU92315I2 (fr) Combinaison comprenant aliskiren, ou un de ses sels pharmaceutiquement acceptable, et amlodipine, ouun de ses sels pharmaceutiquement acceptable
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
SE0101932D0 (sv) Pharmaceutical combinations
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE9802208D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
SE0102055D0 (sv) New Compounds
WO2003053971A8 (en) Pyridoquinoxaline antivirals
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
TW200510370A (en) Urea derivatives
EP1411956B8 (en) Use of oversulfated polysaccharides as inhibitors of hiv

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.